Fibe Aims for ₹1,500 Crore IPO, Eyes Billion-Dollar Valuation by 2026...
08 Aug, 2025
Astonea Labs, a fast-growing pharmaceutical and cosmetic products manufacturer based in Haryana, is set to open its initial public offering (IPO) for subscription on Tuesday, May 27, 2025. The company aims to raise ₹37.67 crore through a fresh issue of 2.79 million equity shares, marking a significant step in its journey to expand both domestically and internationally.
The IPO is structured as a pure fresh issue, with no offer for sale (OFS) component. This means that all proceeds will go directly to the company to fund its future initiatives. The issue has been carefully allocated: 50% is reserved for qualified institutional buyers (QIBs), 35% for retail investors, and 15% for non-institutional investors (NIIs).
Kfin Technologies has been appointed as the registrar for the issue, while Oneview Corporate Advisors is the sole book-running lead manager.
According to the company’s red herring prospectus, the IPO proceeds will be strategically deployed to fuel Astonea Labs’ next phase of growth:
Founded in April 2017, Astonea Labs has rapidly built a diverse portfolio of pharmaceutical and cosmetic products. The company manufactures and markets a wide range of medicines, including antibiotics, anti-cold and antihistamine drugs, as well as treatments for diabetes, cardiovascular diseases, gynecological issues, pain relief, fungal infections, and multivitamins. Its cosmetic product line covers skin, dental, and hair care, offered in various forms such as gels, ointments, creams, lotions, oils, and serums.
Astonea Labs operates a state-of-the-art manufacturing facility spanning 7,500 square meters in Haryana, equipped to meet stringent international standards. The company’s products are marketed under the brands “Glow Up” and “Regero,” and are available both in India and abroad.
The company’s financials reflect robust growth. For the nine months ending December 31, 2024, Astonea Labs reported revenue from operations of ₹69.55 crore and a profit after tax (PAT) of ₹4.10 crore. For the full financial year 2023-24, revenue stood at ₹80.19 crore, a 19.5% increase over the previous year while PAT surged to ₹3.80 crore from ₹66.5 lakh in FY23.
Astonea Labs’ IPO comes amid strong investor interest in the pharmaceutical and cosmeceutical sectors, driven by rising healthcare awareness and demand for personal care products. The company’s focus on expanding into new international markets, enhancing manufacturing capabilities, and investing in technology and marketing positions it well for sustained growth.
With this IPO, Astonea Labs is poised to strengthen its presence in both domestic and global markets, capitalizing on its manufacturing expertise, diverse product range, and commitment to quality.
